Phase I trial evaluating the safety and efficacy of DAR 901 in BCG-vaccinated, HIV-positive adults

Trial Profile

Phase I trial evaluating the safety and efficacy of DAR 901 in BCG-vaccinated, HIV-positive adults

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2014

At a glance

  • Drugs IMM-201 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Mar 2014 New trial record
    • 19 Mar 2014 Planned initiation date changed from 1 Dec 2013 to 1 May 2014, based on information from Dartmouth's Geisel School of Medicine and Aeras.
    • 19 Mar 2014 Status changed from planning to not yet recruiting, according to Dartmouth's Geisel School of Medicine and Aeras.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top